Survival of an elderly patient with lung cancer treated with first-line chemotherapy
Keywords:
survival, adenocarcinoma, advanced non-small lung cancer, aged, chemotherapy.Abstract
Introduction: Lung cancer is taking an increasing toll on the older population as life expectancy increases. However, the efficacy of chemotherapy is difficult to establish and the prognosis of these patients is severe.Objective: Report a case of an older adult patient with advanced non-small cell lung cancer with prolonged survival who received only first-line chemotherapy.
Case report: A 71-year-old non-smoker patient diagnosed with advanced non-small cell lung cancer, adenocarcinoma subtype, with pleural involvement. He started treatment with carboplatin 5 AUC and gemcitabine 1,1 g. In the ninth cycle, reduction of pulmonary nodules was found, but he also had metastases at the D6-D7 level. He started the second line of treatment with carboplatin 5,4 AUC, paclitaxel 200 mg and zolendronic acid at a dose of 4,0 mg. Due to adverse events, the treatment was changed to vinorelbine 2,5 g and zolendronic acid 4.0 mg. After two cycles, the patient died, reaching 21 months of overall survival, only with chemotherapy.
Conclusion: The treatment of the older adult patient with lung cancer is challenging. In the present chemotherapy treatment, the patient was able to achieve 21 months of overall survival, despite the fact that he was not molecularly characterized.
Downloads
Download data is not yet available.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 [acceso: 31/07/2020]; 68(6):394-424. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492
2. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. InternMed J. 2006 [acceso: 01/01/2020]; 36(4):216-20. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1445-5994.2006.01033.x
3. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non - small-cell lung cancer. J ClinOncol. 2010 [acceso: 31/01/2020]; 28(13):2191-7. Disponible en: https://ascopubs.org/doi/10.1200/JCO.2009.25.4052?url_ver=Z39.882003&rfr_
4.Takayuki N, Keiko T, Junji U, Yoshiko K, Nobuyo T, Tadaaki Y, et al. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.Biomed Res Int. 2018 [acceso: 03/03/2020];18:8. Disponible en: https://www.hindawi.com/journals/bmri/2018/8202971/
5.Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, et al. Long-term survivors in stage IV non-small cell lung cancer. LungCancer. 2005 [acceso: 04/04/2020]; 47(1):85-91. Disponible en: https://www.lungcancerjournal.info/article/S0169-5002(04)00301-0/fulltext
6.Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M, et al. Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 2007 [acceso: 03/07/2020]; 27(6 C):4457-60. Disponible en: https://ar.iiarjournals.org/content/27/6C/4457.long
7.Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The southwest oncology group experience. J ClinOncol. 1991 [acceso: 04/10/2020]; 9(9):1618-26. Disponible en: https://ascopubs.org/doi/pdf/10.1200/JCO.1991.9.9.1618
8.Jara Exebio JJ, Cabrera Sandoval RN, Amaro Palomino JK, Revilla López JC. Adenocarcinoma pulmonar metastásico con evolución favorable al tratamiento con ITK-EGFR en un paciente fumador Metastaticlung adenocarcinoma favorable outcomewith ITK-EGFR treatment in a smoker. AnFacmed . 2011[acceso: 02/09/2020]; 76:199-202. Disponible en: https://www.scielo.org.pe/pdf/afm/v76n2/a14v76n2.pdf
9.Castro C, Cardona F, Revéiz L, Serrano J, Carranza H, Vargas C, et al. Cáncer de pulmón de célula no pequeña metastásico. Acta Médica Colomb . 2010[acceso:04/04/2020]; 35(2):53-81. Disponible en: https://www.scielo.org.co/pdf/amc/v35n2/v35n2a04.pdf
10.Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. LungCancer. 2010 [acceso: 05/07/2020]; 67(1):120-3. Disponible en: https://www.lungcancerjournal.info/article/S0169-5002(09)00137-8/fulltext
11. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, et al. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J ThoracOncol .2016 [acceso: 05/05/2020]; 11(4):556-65. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1556086415002658
2. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. InternMed J. 2006 [acceso: 01/01/2020]; 36(4):216-20. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1445-5994.2006.01033.x
3. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non - small-cell lung cancer. J ClinOncol. 2010 [acceso: 31/01/2020]; 28(13):2191-7. Disponible en: https://ascopubs.org/doi/10.1200/JCO.2009.25.4052?url_ver=Z39.882003&rfr_
4.Takayuki N, Keiko T, Junji U, Yoshiko K, Nobuyo T, Tadaaki Y, et al. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.Biomed Res Int. 2018 [acceso: 03/03/2020];18:8. Disponible en: https://www.hindawi.com/journals/bmri/2018/8202971/
5.Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, et al. Long-term survivors in stage IV non-small cell lung cancer. LungCancer. 2005 [acceso: 04/04/2020]; 47(1):85-91. Disponible en: https://www.lungcancerjournal.info/article/S0169-5002(04)00301-0/fulltext
6.Satoh H, Ishikawa H, Ohara G, Kagohashi K, Kurishima K, Ohtsuka M, et al. Long-term survivors after chemotherapy in advanced non-small cell lung cancer. Anticancer Res. 2007 [acceso: 03/07/2020]; 27(6 C):4457-60. Disponible en: https://ar.iiarjournals.org/content/27/6C/4457.long
7.Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The southwest oncology group experience. J ClinOncol. 1991 [acceso: 04/10/2020]; 9(9):1618-26. Disponible en: https://ascopubs.org/doi/pdf/10.1200/JCO.1991.9.9.1618
8.Jara Exebio JJ, Cabrera Sandoval RN, Amaro Palomino JK, Revilla López JC. Adenocarcinoma pulmonar metastásico con evolución favorable al tratamiento con ITK-EGFR en un paciente fumador Metastaticlung adenocarcinoma favorable outcomewith ITK-EGFR treatment in a smoker. AnFacmed . 2011[acceso: 02/09/2020]; 76:199-202. Disponible en: https://www.scielo.org.pe/pdf/afm/v76n2/a14v76n2.pdf
9.Castro C, Cardona F, Revéiz L, Serrano J, Carranza H, Vargas C, et al. Cáncer de pulmón de célula no pequeña metastásico. Acta Médica Colomb . 2010[acceso:04/04/2020]; 35(2):53-81. Disponible en: https://www.scielo.org.co/pdf/amc/v35n2/v35n2a04.pdf
10.Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. LungCancer. 2010 [acceso: 05/07/2020]; 67(1):120-3. Disponible en: https://www.lungcancerjournal.info/article/S0169-5002(09)00137-8/fulltext
11. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, et al. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J ThoracOncol .2016 [acceso: 05/05/2020]; 11(4):556-65. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1556086415002658
Published
2021-10-01
How to Cite
1.
Quintana Blancos OA, Vallejos Garcia RE, Olmos Soldevilla RC, Salvador Carrillo JF, Salinas Paz JL. Survival of an elderly patient with lung cancer treated with first-line chemotherapy. Rev Cubana Med Milit [Internet]. 2021 Oct. 1 [cited 2025 Apr. 4];50(4):e02101154. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/1154
Issue
Section
Case Presentation
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
